Want to join the conversation?
Denver, Colorado-based $DVA said that most of the company's growth internationally have been through acquisitions. In Kidney Care, the company's strategic position in US is strong. In 4Q15, the company recorded an estimated accrual of $23MM for potential damages and liabilities in its DaVita Rx pharmacy business.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.